Evidence map›Paper›PMID 39851968›Full record

ArticleCurrent oncology (Toronto, Ont.)2025

Real-World Experience with CDK4/6 Inhibitors in the First-Line Palliative Setting for HR+/HER2- Advanced Breast Cancer.

Ram Patel, John Mathews, Caroline Hamm, Swati Kulkarni, Rasna Gupta, Tarquin Opperman, John Dean Chiong, Abdullah Nasser

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Current oncology (Toronto, Ont.), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed.

  1. Cancers · 2026
    Review
  2. Article
  3. Article
  4. Article
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Ram PatelSchulich School of Medicine and Dentistry, Western University, London, ON N6A 3K7, Canada.ORCID 0000-0003-0887-6931
John MathewsDepartment of Medical Oncology, Windsor Regional Hospital, Windsor, ON N8W 1L9, Canada.
Caroline HammDepartment of Medical Oncology, Windsor Regional Hospital, Windsor, ON N8W 1L9, Canada.
Swati KulkarniDepartment of Medical Oncology, Windsor Regional Hospital, Windsor, ON N8W 1L9, Canada.
Rasna GuptaDepartment of Medical Oncology, Windsor Regional Hospital, Windsor, ON N8W 1L9, Canada.
Tarquin OppermanSchulich School of Medicine and Dentistry, Western University, London, ON N6A 3K7, Canada.
John Dean ChiongSchulich School of Medicine and Dentistry, Western University, London, ON N6A 3K7, Canada.ORCID 0000-0003-2515-6864
Abdullah NasserSchulich School of Medicine and Dentistry, Western University, London, ON N6A 3K7, Canada.ORCID 0000-0002-1302-2861

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

introductionCDK4/6 inhibitors in combination with aromatase inhibitors (AIs) are the standard first-line treatment for hormone receptor-positive (HR+), HER2-negative (HER2-) metastatic breast cancer. Landmark trials have demonstrated a comparable progression-free survival (PFS) across CDK4/6 inhibitors, but the overall survival (OS) outcomes have varied. This study aimed to evaluate the real-world PFS and OS for palbociclib and ribociclib when combined with AIs in patients with HR+/HER2- advanced breast cancer. MATERIALS AND

methodsThis was a retrospective chart review of adult patients with HR+/HER2- metastatic breast cancer treated at a single academic center between 1 January 2015 and 1 December 2022. The baseline demographics, clinical characteristics, and treatment details were extracted. A Kaplan-Meier analysis was used to estimate the PFS and OS, and differences between the treatment groups were assessed using the log-rank test. Cox proportional hazards models were constructed to adjust for confounding factors.

resultsSeventy-five patients were included in the final analysis. The cohort was predominantly female (98.7%) and postmenopausal (77.3%), with 52.0% having de novo stage IV disease. Palbociclib was prescribed to 74.7% of the patients, and ribociclib to 25.3%. The patients receiving ribociclib were significantly younger (57.6 vs. 67.5 years,

conclusionIn this real-world analysis, palbociclib demonstrated a median PFS consistent with the results from landmark trials, although the observed OS was shorter. The ribociclib-treated patients had a numerically longer PFS and OS compared with those treated with palbociclib, but the differences were not statistically significant. The discontinuation rates were similar between the two groups.

Indexed as

Antineoplastic Combined Chemotherapy ProtocolsBreast NeoplasmsCyclin-Dependent Kinase 4Cyclin-Dependent Kinase 6Protein Kinase InhibitorsAcrylamidesAdultAgedAminopyridinesAromatase InhibitorsErb-b2 Receptor Tyrosine KinasesFemaleHumansMiddle AgedPalliative CarePiperazinesAcrylamidesAminopyridinesAromatase InhibitorsCDK4 protein, humanCDK6 protein, humanCyclin-Dependent Kinase 4Cyclin-Dependent Kinase 6ERBB2 protein, humanErb-b2 Receptor Tyrosine KinasespalbociclibPiperazinesProtein Kinase InhibitorsPurinesPyridinesReceptors, EstrogenReceptors, Progesteroneribociclibaromatase inhibitorscyclin-dependent kinase inhibitorsmetastatic breast cancerreal-world evidencesurvival analysis

Identifiers

PMID39851968
PMCPMC11764237

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.